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Abstract
Objective—Sympathetic nerve innervation of vascular smooth muscle cells (VSMCs) is a major 
regulator of arteriolar vasoconstriction, vascular resistance, and blood pressure (BP). Importantly, 
α-adrenergic receptor stimulation, which uniquely couples with Pannexin 1 (Panx1) channel-
mediated ATP release channels in resistance arteries, also requires localization to membrane 
caveolae. Here we test if localization of Panx1 to caveolin-1 promotes channel function (stimulus-
dependent ATP release and adrenergic vasoconstriction) and is important for BP homeostasis.
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Approach and Results—We use in vitro VSMC culture models, ex vivo resistance arteries, 
and a novel inducible VSMC-specific caveolin-1 knockout mouse to probe interactions between 
Panx1 and caveolin-1. We report that Panx1 and caveolin-1 co-localized on the VSMC plasma 
membrane of resistance arteries near sympathetic nerves in an adrenergic stimulus-dependent 
manner. Genetic deletion of caveolin-1 significantly blunts adrenergic stimulated ATP release and 
vasoconstriction, with no direct influence on endothelium-dependent vasodilation or cardiac 
function. A significant reduction in mean arterial pressure (Total= 4 mmHg; Night= 7 mmHg) 
occurred in mice deficient for VSMC caveolin-1. These animals were resistant to further BP 
lowering using a Panx1 peptide inhibitor PxIL2P1, which targets an intracellular loop region 
necessary for channel function.
Conclusions—Translocalization of Panx1 to caveolin-1-enriched caveolae in VSMCs augments 
the release of purinergic stimuli necessary for proper adrenergic-mediated vasoconstriction and BP 
homeostasis.
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INTRODUCTION
In the peripheral circulatory system, blood pressure (BP) homeostasis is largely regulated by 
the contractile state of the smooth muscle cells (VSMCs) in the wall of resistance arteries. 
Resistance arteries are small diameter (≤200 μm) arterioles that are composed of an intimal 
endothelial layer, a tunica media consisting of one to two VSMC layers1, and are 
functionally defined by the ability to respond to changes in intraluminal pressure to control 
vascular resistance and blood flow. Sympathetic nerve innervation of VSMCs is a major 
regulatory pathway that induces VSMC constriction, thus altering arteriolar lumen diameter 
and increasing the amount of vascular resistance2,3. While much is already known about the 
induction of rapid (purinergic) and potentiated (adrenergic) sympathetic nerve-derived 
stimuli on function of resistance arteries4, less is known about the identity of downstream 
VSMC signaling molecules that subsequently coordinate VSMC-derived stimuli in the 
arteriolar wall. Signaling through α-adrenergic receptors (α-ARs) and activation of plasma 
membrane-associated signaling molecules may be compartmentalized by caveolae near 
areas of sympathetic innervation2,5–8.
Caveolae are specialized plasma membrane domains that play an important role in 
intracellular signaling, cellular transport, and differentiation9–11. Caveolae are defined by 
their hallmark plasma membrane morphology, consisting of 80–100nm-wide membrane 
invaginations, and by their composition of oligomeric coat-forming proteins called 
caveolins12. Of the three caveolin isoforms, caveolin-1 is essential for caveolae formation 
and function13–15. Caveolin-1 has been shown to regulate vasoconstriction responses in 
small arterioles and to influence BP homeostasis in animal models13,16–18. Importantly, 
caveolin-1 is expressed in VSMCs of small arteries and acts as a membrane-scaffold protein 
for both α-ARs and downstream G-protein dependent vasoconstriction signaling 
molecules19,20, suggestive of a role in adrenergic-mediated vasoconstriction.
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Recently, our group and others21–24 have elucidated in mouse and humans an α–AR 
signaling axis that activates Pannexin 1 channels. Pannexins are a family of transmembrane 
channel-forming glycoproteins that have emerged as the physiological conduit for controlled 
ATP release from vascular and non-vascular cell types25–27. We have previously reported 
that Panx1 expression is polarized within the vascular tree, with high expression levels in 
VSMCs of resistance arteries (e.g. mesenteric, cremasteric, thoracodorsal, and coronary), but 
is not present in large conduit vessels such as the femoral and carotid arteries, and the 
aorta28. This expression pattern suggests a unique role for Panx1 in regulating vascular 
resistance. Using Panx1 pharmacological inhibitors and inducible VSMC-specific Panx1 
knockout mice, we have further demonstrated that Panx1-mediated ATP release and 
vasoconstriction are uniquely coupled with α-adrenergic stimulation and are crucial for 
maintaining BP homeostasis21,22. Multiple groups have confirmed the activation of Panx1 
channels by α-adrenergic stimulation29–31, thus demonstrating ATP release through Panx1 
as a significant physiological pathway for integrating and coordinating VSMC-derived 
constriction responses4,32.
In the present study, we hypothesized that caveolin-1 acts as a molecular scaffold that 
concentrates VSMC Panx1 to areas important for sympathetic nerve innervation, thus 
supporting α-adrenergic vasoconstriction and BP homeostasis. In response to the α-
adrenergic agonist phenylephrine we observed a novel interaction and co-localization of 
caveolin-1 and Panx1 to regions of innervation at the VSMC plasma membrane. To 
investigate the functional role of caveolin-1 during α-adrenergic mediated responses, we 
generated an inducible, VSMC-specific caveolin-1 knockout mouse model. We show that 
VSMC-derived caveolin-1 is required for α-adrenergic stimulated ATP release and 
adrenergic vasoconstriction. Deletion of VSMC caveolin-1 results in a significant reduction 
in mean arterial BP, particularly during the nocturnal (active) period when sympathetic drive 
is high. Furthermore, we suggest that caveolin-1 mediated BP effects are regulated through 
the Panx1 intracellular loop regulatory domain, previously identified to be indispensable for 
α-adrenergic vasoconstriction22.
METHODS
Data and Materials
All data will be made available upon request by the corresponding authors at the University 
of Virginia.
Animals
All animals were cared for under the provisions of the University of Virginia Animal Care 
and Use Committee and the National Institute of Health guidelines for the care and use of 
laboratory animals. Male C57BL/6 mice between 10–15 weeks of age were purchased from 
Taconic. Male smooth muscle myosin heavy chain-Cre recombinase modified estrogen 
receptor binding domain (SMMHC-CreERT2) modified mice, a kind gift from S. 
Offermanns33, were used for experimentation due to the restrictive presence of Cre 
recombinase on the Y chromosome. Aortae from Connexin 43 globally deficient mice 
(Cx43−/−) were harvested at birth. Mice harboring lox-P recombination sites for caveolin-1 
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(Caveolin-1fl/fl) were generated as previously described34. SMMHC-CreERT2 mice were 
mated with Caveolin-1fl/fl mice to specifically delete caveolin-1 from vascular smooth 
muscle cells. Induction of Cre-mediated deletion was performed at 6 weeks of age via ten 
daily intraperitoneal injections (100 μl) of tamoxifen (1 mg/kg) to generate caveolin-1 null 
animals (SMMHC-CreERT2+/Cav1Δ/Δ) or ten daily 100 μl injections of peanut oil (vehicle 
control) to generate control animals (SMMHC-CreERT2+/Cav1fl/fl). All animal experiments 
were performed at the least 14-days from the final injection with tamoxifen and/or peanut oil 
since the Cre recombinase is located on the Y. Mice lacking the Cre recombinase allele were 
also used as tamoxifen controls. Please see the Major Resources Table in Supplemental 
Material for detail.
Cell Culture
Primary human vascular coronary smooth muscle cells (VSMCs) were purchased from 
Lonza (Cat# CC-2583). All cells were maintained under standard cell culture conditions (5% 
CO2 at 37°C) in smooth muscle growth media (Lonza; Cat# CC-3181) supplemented with 
smooth muscle growth factors (Lonza; Cat# CC-3182) and 10% fetal bovine serum (FBS) 
(Lonza; Cat# CC-4102D). Cells were used at 8 passages or fewer for in vitro experiments. 
For all experiments, VSMCs were serum deprived for 48hrs in 0.2% FBS to induce 
contractile phenotypes35–37.
Ultrastructure electron microscopy
Mouse arteries were processed for ultrastructure TEM as previously described38. Images 
were obtained using a Joel 1230 transmission electron microscope at the Advanced 
Microscopy Core at the University of Virginia.
Proximity Ligation Assay (PLA) and Immunofluorescence
Thoracodorsal arteries (TDA) were isolated as previously described39, incubated in Krebs-
HEPES physiological saline buffer, and treated with phenylephrine (20 μmol/L) in a single 
well of a 96-well dish. TDAs were then placed in a 1.5 mL Eppendorf tube, fixed in 4% 
paraformaldehyde, and subjected to en face proximity ligation assay using the Duolink in 
situ PLA detection kit (Sigma) as previously described by us40. Sympathetic nerves were 
labeled using anti-mouse tyrosine hydroxylase antibody (Abcam #ab112; 1:250 dilution) 
and visualized using an Alexa Fluor 568 secondary antibody (Life Technologies #A-21099; 
1:400 dilution). Primary antibodies for PLA labeling included anti-mouse Caveolin-1 (BD 
Biosciences# 610406, clone 2297; 1:400 dilution) and anti-mouse Panx1 CT395 
(characterized by Penuela et al,41 1:300 dilution). PLA detection was performed according 
to manufacturer’s protocol. Immunofluorescence staining on aorta and TDAs was performed 
as previously described28. Primary antibodies for immunofluorescence included anti-rabbit 
Cx43 antibody (Sigma #C6219; 1:300 dilution) and vesicular nucleotide transport protein 
(anti-mouse VNUT; a kind gift from Dr. Chen Li, 1:200 dilution). All images were acquired 
using an Olympus Fluoview 1000 confocal microscope. PLA punctate spots were counted 
per 100um2 cell area. Caveolin-1 deletion was quantified using batch-processed tissue and 
threshold generated images. The relative fluorescence intensity within the smooth muscle 
cell layer (demarcated by co-association with Acta2 staining, and between the boundary 
lines of the IEL and adipose tissue) was measured using ImageJ42 and normalized to Acta2 
DeLalio et al. Page 4
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2019 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
positive area. Co-staining for smooth muscle cells (Acta2; Sigma #A2547, 1:500 dilution) 
and endothelial cells (PECAM-1; Santa Cruz #sc28188, 1:400 dilution) was performed. Data 
are presented as mean ± SEM. A students t-test was performed for statistical significance. *p 
< 0.05.
Live cell imaging
Confocal imaging was performed with a Leica TCS SP8 confocal microscope. Human 
VSMCs were cultured as indicated above and plated on 100μg/mL poly-D-lysine (PDL) on 
cover glass. Cells were transfected with plasmids encoding Panx1-RFP43 and Caveolin-1-
GFP using jetPRIME (Polyplus transfection/VWR) according to the manufacturer’s 
protocol. Image acquisition and co-distribution analyses were performed double-blinded to 
treatment conditions with identical imaging parameters. For live imaging, baseline images 
were collected at 30 sec intervals for 2 min using a 20X (0.7 NA) objective. Importantly, the 
large cellular size (range of lengths) permitted imaging of only one cell per field of view. 
Treatment with phenylephrine (100 μmol/L; Sigma-Aldrich), ATP (500μmol/L; Sigma–
Aldrich) or vehicle control (water) was performed by removing half the volume of control 
media and replacing it with the same volume of media containing 2X agonist. Images were 
collected at 30 sec intervals up to 5 min. The z-section containing the largest cellular area 
was selected for Mander’s coefficient analysis of Panx1-Cav1 co-distribution using the 
JACoP plugin in FIJI44. All post-treatment data were normalized to the average obtained at 
baseline. Data were collected from N=5–11 cells per experimental condition and analyzed 
using a two-way ANOVA for time and treatment (Time: F (10, 250) = 3.027, P = 0.0012; 
Treatment: F (2, 25) = 4.673, P = 0.0189; Subjects: F (25, 250) = 19.41, P < 0.0001) with 
Dunnett’s posthoc (P<0.05 for phenylephrine at 0.5 min, for ATP) with GraphPad Prism 
v5.0.
Membrane fractionation and isolation of caveolin-1 enriched membrane domains
Human VSMCs were grown to confluence and incubated in media containing 0.2% FBS for 
48 hr prior to use. VSMCs were washed with PBS and re-equilibrated for 10 min in Krebs 
buffer (mmol/L: 118.4 NaCl, 4.7 KCl, 1.2 MgSO4, 4 NaHCO3, 1.2 KH2PO4, 10 Hepes, 6 
Glucose) containing 2 mmol/L CaCl2. VSMCs were treated with 100μmol/L phenylephrine 
or vehicle control, scraped with a cell scraper and lysed in ice-cold detergent-free lysis 
buffer (500 mmol/L Na2CO3, 50 mmol/L NaF, 2 mmol/L Na3VO4, pH 11, supplemented 
with 1 mg/mL of protease inhibitor cocktail (Sigma) and 1 mg/mL P2 and P3 phosphatase 
inhibitor cocktails (Sigma)). Lysates were homogenized using a dounce homogenizer (10 
strokes) and sonication (25 pulses for 1 sec) on ice. Lysates were either fractioned using 
differential centrifugation (40,000 rpm; 1hr Beckman XL80 ultracentrifuge with Sw55Ti 
rotor) or using centrifugation across a sucrose gradient. To create a sucrose gradient, sucrose 
solutions were mixed in MBS-sodium carbonate buffer (25 mmol/L MES, 0.5 M NaCl, 250 
mmol/L Na2CO3) to 85%, 30%, and 5% by mass by adding 42.5 g, 15 g, or 2.5 g of sucrose, 
respectively, to 50 mL of MBS. Lysates were mixed with equal volume of 85% sucrose 
solution to create 42.5% layer. 1.5 mL of 42.5% layer was added to the bottom of a Sw55Ti 
ultracentrifuge tube, after which a 5–42.5% discontinuous sucrose gradient was formed by 
adding, dropwise on top of previous layers, 1 mL of 30% sucrose solution followed by 1 mL 
of 5% sucrose solution. Gradients were centrifuged at 42,000 rpm for 18 hr in a Beckman 
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XL80 ultracentrifuge with Sw55Ti rotor. Ten fractions of 350 μL each were removed starting 
from the top of the gradient and analyzed using western blot with antibodies for rabbit anti-
human Pannexin 1 (characterized by Penuela et al.45 1:1000 dilution) and mouse anti-
caveolin-1 (BD Biosciences #610406; 1:1000 dilution). Co-immunoprecipitation was 
performed using either Pannexin1 antibodies (1:50 dilution) in conjunction with anti-rabbit 
IgG Dynabeads (Invitrogen) respectively. To perform co-immunoprecipitations, caveolin-1-
enriched fractions (4–5) and non-enriched fractions (7–8) were combined and total protein 
from each was measured by BCA assay. Equal amounts of protein from each pair of 
fractions was used for co-immunoprecipitation as described above. Five independent 
experiments were performed. The ratio of caveolin-1 signal was normalized to the amount of 
immunoprecipitated Pannexin 1. Data are represented as mean ±SEM. A students t-test was 
performed for statistical significance. *p < 0.05.
Western blot
After stimulation with adrenergic agonists, human VSMCs were homogenized in ice-cold 
NP-40 extraction buffer (50mmol/L Tris-HCL, 150mmol/L NaCl, 5mmol/L EDTA, 1% 
deoxycholate, 1% NP-40 and 1% Triton-X100 in PBS and pH adjusted to 7.4) containing 
protease inhibitor cocktail (Sigma) and P2 / P3 phosphatase inhibitor cocktail (Sigma). Cell/
tissue lysates were incubated at 4°C for 10 min to solubilize proteins, sonicated for 12 pulses 
for 1 sec each, and centrifuged for 10 min at 12,000 rpm to pellet cell debris. Protein 
concentration was determined using the BCA method (Pierce). 10–20 μg of total protein was 
loaded into each sample well. Samples were subjected to SDS gel electrophoresis using 4–
12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membrane for 
immunoblotting. Membranes were blocked for 1 hour at room temperature in a solution 
containing 3% BSA in Tris buffered saline, then incubated overnight at 4°C with primary 
antibodies against rabbit anti-Pannexin 1 (Cell Signaling Technology #91137 (D9M1C); 
1:1000 dilution), rabbit anti-Caveolin-1 (BD Biosciences #610059; 1:1000 dilution), rabbit 
anti-transferrin receptor (Abcam #ab84036; 1:1000 dilution) and mouse anti-GAPDH 
(Sigma mAb #G8795; 1:10,000). Membranes were washed and incubated in LiCOR IR Dye 
secondary antibodies (1:15,000) for 1 hour and viewed/quantified using the LiCOR Odyssey 
with Image Studio software. Representative western blot images have been cropped for 
presentation.
Pressure myography
Pressure myography was performed on TDAs as previously described46. Briefly, mice were 
sacrificed using CO2 asphyxia. TDAs were microdissected, cannulated on glass pipettes in a 
temperature-controlled pressure arteriography chamber, and pressurized to 80mmHg. After a 
30-min equilibration period in Krebs-HEPES with 2mmol/L Ca2+, vessels were treated with 
cumulative doses of phenylephrine (PE, 10−10–10−3 mol/L) applied to the bath. The luminal 
diameter was analyzed using digital calipers in the DMT vessel acquisition software (Danish 
Myo Technology). Smooth muscle cell viability was assessed using serotonin (1 μmol/L) 
and KCl (30 mmol/L). Endothelial-dependent vasodilation was measured using cumulative 
doses of acetylcholine (10−11–10−2 mol/L) as previously described46. A two-way analysis of 
variance (ANOVA) with Bonferonni post-hoc test was performed for multiple comparisons. 
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Concentration-effect curves were fitted to the data using four-parameter, non-linear 
regression curve fitting using GraphPad (version 7).
ATP measurements
For the measurement of extracellular ATP, intact TDAs of equal length were placed in 
individual wells of a 96-well plate in Krebs-Hepes physiologic solution for 15 min. The 
ectonucleotidase inhibitor ARL 67156 trisodium (Tocris; 100μmol/L) was added 30 min 
prior to treatment with contractile agonists as previously described22. Vasoconstrictor 
compounds were added to the incubation media for 5 min to allow ATP accumulation: 
Phenylephrine (PE; 20μmol/L), Norepinephrine (NE; 20 μmol/L), Serotonin (5-HT; 
40nmol/L), and Endothelin-1 (ET-1; 40nmol/L) (all purchased from Sigma). Following 
stimulation, the media surrounding the vessel was collected and immediately placed into 
pre-chilled 1.5 mL Eppendorf tubes on ice. All samples were centrifuged at 10,000 x g for 5 
min. For intracellular ATP measurements, TDAs were microdissected, cleaned of adventitia, 
and cut into equal 10.5mm vessel segments. Segments were individually lysed in ATP lysis 
buffer according to manufacturer’s protocol, spun at 10,000 x g for 1 min, and samples 
collected. ATP concentration in the incubation media was quantified using the ATP 
bioluminescence assay kit HSII (Roche) using a FluoStar Omega plate reader luminometer. 
Extracellular ATP measurements for each sample were tested in triplicate and calculated 
using an ATP standard curve for all experiments. Intracellular ATP measurements were 
measured from three vessel segments (one TDA in triplicate). Data are presented as % 
change in ATP release from baseline (unstimulated) or as the concentration of ATP in the 
media compared to control samples. One-way ANOVA with Tukey’s test was performed for 
statistical significance of extracellular ATP. A Kruskal-Wallis (one-way ANOVA on ranks) 
with Dunn’s post-hoc test performed for intracellular ATP. Significance denoted as *p < 
0.05.
Blood pressure telemetry
Blood pressure was measured using telemetry equipment as previously described22. Briefly, 
telemeters (Data Sciences International [DSI]) were implanted in C57BL/6 or SMMHC-
CreERT2+/Cav1fl/fl (SMC-Cav1fl/fl) mice. Under isoflurane anesthesia, the catheter of a 
single telemetry unit (TA11PA-C10, DSI) was implanted in the left carotid artery and the 
transmitter placed in a subcutaneous pouch along the right flank of the mouse. After 
implantation surgery, mice were allowed to recover for 7 days to re-establish normal 
circadian rhythms and blood pressure. For experiments using inducible Cre recombinase, 
mouse blood pressure baselines were continuously recorded using Dataquest A.R.T. 20 
software (DSI) for 5 days after normal recovery and before starting intraperitoneal 
tamoxifen injections or vehicle control (peanut oil) for 10 days. Blood pressure was recorded 
for an additional 5 days starting 24 hr after the last tamoxifen injection. Change in MAP 
(ΔMAP) was calculated by subtracting the average MAP measured before tamoxifen 
injections to the MAP after tamoxifen injections. Diurnal (inactive period) MAP was 
measured during animal’s light cycle: 6:00 a.m. to 5:59 p.m., and nocturnal (active period) 
MAP was measured during the animal’s dark cycle: 6:00 p.m. to 5:59 a.m. MAPs before and 
after tamoxifen injections were compared with a Wilcoxon test (nonparametric paired t-test). 
C57BL/6 mice similarly received intraperitoneal injections of tamoxifen or vehicle control, 
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and basal blood pressure was measured as for transgenic animals. For assessment of the 
blood pressure effects of the PxIL2P peptide inhibitor (formerly referred to as PxIL2P1 
peptide22), animals were intraperitoneally injected with saline vehicle control or peptide (20 
mg/kg in a volume not exceeding 100 μL). Blood pressure was recorded for 2 hr after 
injection, and the MAP data was averaged and compared to the basal blood pressure. 
Change in MAP (ΔMAP) was calculated by subtracting the baseline MAP 30 min before 
injection from the MAP measured during the final 30 min of the 2 hr treatment period. Data 
represent mean ±SEM. Two-way ANOVA with Tukey post-hoc test was performed for 
assessment of MAP before and after tamoxifen/vehicle control induction and for mice 
treated with scrambled peptide or PxIL2P peptide inhibitor.
Cardiac magnetic resonance imaging and histology
All MRI animal studies were performed under protocols that comply with the Guide for the 
Care and Use of Laboratory Animals (NIH publication no. 85-23, Revised 1996) and were 
approved by the Animal Care and Use Committee at our institution (ACUC, UVA). Mice 
were positioned supine in the scanner and body temperature was maintained at 36 ± 0.5°C 
using thermostatic circulating water. Anesthesia used was 1.25% isoflurane in O2 inhaled 
through a nose cone during imaging. A 30 mm-diameter cylindrical birdcage RF coil 
(Bruker) with an active length of 70 mm was used, and heart rate, respiration, and 
temperature were monitored during imaging using a fiber optic, MR-compatible system 
(Small Animal Imaging Inc., Stony Brook, NY). MRI was performed on a 7 Tesla (T) 
Clinscan system (Bruker, Ettlingen, Germany) equipped with actively shielded gradients 
with a full strength of 650 mT/m and a slew rate of 6666 mT/m/ms. Baseline LV structure 
and function were assessed47. Six short-axis slices were acquired from base to apex, with 
slice thickness equal to 1mm, in-plane spatial resolution of 0.2 × 0.2 mm2, and temporal 
resolution of 8–12 ms. Baseline ejection fraction (EF), end-diastolic volume (EDV), end-
systolic volume (ESV), myocardial mass, wall thickness, and wall thickening were measured 
from the cine images using the freely available software Segment version 2.0 R5292 (http://
segment.heiberg.se). EDV and ESV were then indexed to body mass (EDVI and ESVI, 
respectively). Mass to volume ratio (MVR) was calculated as the ratio of myocardial mass to 
EDV.
Plasma Renin ELISA
Mice were anesthetized using 2,2-Dicholor-1,1-difluoroethyl methyl ether (ThermoFisher; 
#76-38-0). 100–150 μl of whole blood was collected from mouse tail veins using 
heparinized capillary tubes into 1.5mL Eppendorf, stored on ice, and centrifuged for 15 
minutes at 1000rpm. Plasma was aliquoted, snap frozen, and stored at −80°C. Plasma renin 
concentration was measured using a total renin ELISA (RayBio; #ELM-Ren1) against a 
renin standard curve with 1:15 dilution of samples. Student’s t-test (two tailed) was 
performed for significance.
Statistics
All data were analyzed using GraphPad Prism v5.0 for live cell image analysis or v7.0 
software for all other analyses. Briefly, D’Agostino-Pearson tests were used to determine 
normality. Brown-Forsthe/Barlett’s tests were used to determine equal variance for ANOVA 
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and F-test was used to determine equal variance for t-test in GraphPad Prism v7.0 software. 
Data that passed normality tests and equal variance tests were analyzed by t-test for two 
groups or ANOVA for three or more groups. Data that were not normally distributed were 
analyzed by Kruskal-Wallis test (three or more groups). Post-hoc analysis for multiple 
comparisons were selected as appropriate to test for statistical significance; * p < 0.05, ** p 
< 0.01, ***p<0.001. Results are presented as mean ± SEM.
RESULTS
Caveolae are specialized plasma membrane domains that facilitate interactions between 
signaling proteins (i.e. Gq, PLC, Src, etc12,48,49) and membrane receptors (i.e. α-adrenergic 
receptors49). These structures are found in endothelium and smooth muscle; however, their 
signaling functions are much less studied in smooth muscle. In electron micrographs, we 
consistently observe caveolae contained in arteriolar smooth muscle in proximity to 
sympathetic nerves (Supplemental Figure I). For this reason, we hypothesized that the 
caveolin-1 protein, the main component to caveolae, may associate with Panx1, which is 
activated in response to adrenergic stimulation.
In initial experiments, we performed live-cell confocal microscopy using in vitro human 
VSMC culture systems to measure the distribution and co-localization of exogenously 
expressed RFP-tagged Panx1 and GFP-tagged caveolin-1 following phenylephrine 
stimulation (Figure 1A). Baseline fluorescence measurements were recorded for 2 min prior 
to stimulation with phenylephrine (100 μmol/L), vehicle control, or high concentration ATP 
(500 μmol/L) to promote Panx1 internalization. A strong and significant co-distribution was 
observed between caveolin-1 and Panx1 at 30 seconds of phenylephrine stimulation at the 
plasma membrane (Figure 1A–B), which persisted above control fluorescence, although not 
to statistically significant levels (Figure 1B–C). Conversely, treatment with high-
concentration ATP caused a significant and continuous reduction in co-localized signal, 
consistent with internalization and loss of Panx1 on the cell surface50,51 that is independent 
of caveolin-1 mediated endocytosis43. Vehicle control-treated cells showed no changes in 
fluorescence co-localization from baseline.
To confirm observations from live-cell imaging experiments, we next performed in vitro cell 
fractionation and co-immunoprecipitation assays using in vitro VSMC culture systems to 
probe for endogenous interactions between Panx1 and caveolin-1 at the plasma membrane. 
We found that caveolin-1 and Panx1 localize to membrane-associated fractions (Figure 1D) 
and specifically overlap in caveolin-1-enriched sucrose-gradient fractions, suggesting partial 
localization of Panx1 to lipid microdomains containing caveolin-1 (Figure 1E). To determine 
if caveolin-1 and Panx1 interact following adrenergic stimulation, we acutely treated 
VSMCs with phenylephrine (20 μmol/L). Fractions enriched or deficient in caveolin-1 were 
isolated and Panx1 was precipitated using a protein specific antibody45. We found that 
caveolin-1 from enriched fractions significantly co-precipitated with Panx1 after adrenergic 
stimulation (Figure 1F), suggesting that plasma membrane complexes containing caveolin-1 
and Panx1 form following adrenergic stimulation and may act to facilitate channel function.
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Panx1-mediated ATP release and subsequent vasoconstriction are specifically mediated 
through α-AR activation21,22,29–31. Based on our initial observations and the in vitro 
biochemical findings herein (Figure 1F), we first tested if caveolin-1 and Panx1 similarly 
interact in VSMCs of ex-vivo isolated mouse resistance arteries. We performed proximity 
ligation assays (PLA) between Panx1 and caveolin-1 on TDAs and assessed the focal plane 
where sympathetic nerves innervate VSMC (Supplemental Figure II). Sympathetic nerves 
were specifically labeled with tyrosine hydroxylase. In control experiments using PLA 
secondary antibodies alone or IgG controls, we could not detect PLA punctate signals (red 
puncta indicate protein associations when PLA probes <40nm in apposition) – only 
sympathetic nerves could be viewed (Figure 2A–B). Next, we performed PLA for caveolin-1 
and Panx1. Here we observed relatively few positive red punctate signals under control 
conditions (Figure 2C); however, following acute (1 min) phenylephrine stimulation (20 
μmol/L), we observed an induction of PLA signal, which predominantly localized at the 
VSMC plasma membrane near areas of sympathetic nerve innervation (Figure 2D–E). As a 
control, TDA smooth muscle and sympathetic nerves were also analyzed for Cx43 
expression, but it was not detected (Supplemental Figure III). The neuronal vesicular 
nucleotide transporter (VNUT) was also analyzed, but was only observed in sympathetic 
nerves, and not VSMCs as anticipated (Supplemental Figure III). These data demonstrate 
the formation of potential signaling microdomains where caveolin-1 and Panx1 are recruited 
together following adrenergic stimulation.
To investigate the functional and physiological role of VSMC caveolin-1 during α-AR 
vasoconstriction, we generated an inducible, VSMC-specific caveolin-1 knockout mouse 
model (SMC-Cav1fl/fl), which upon induction of Cre recombinase deletes exon 2 of 
caveolin-1 (SMC-Cav1Δ/Δ) (Figure 3A–B). Caveolin-1 deletion was specific for VSMCs of 
resistance arteries, not affecting caveolin-1 expression in CD31 positive endothelial cells 
(Figure 3C–D). Due to the well-established contribution of Panx1-mediated ATP release 
during adrenergic stimulation21,22,29,52, we measured vasoconstrictor-dependent ATP release 
from isolated resistance arteries. Using a luminescence-based assay, we observed a 
caveolin-1 dependent response, whereby ATP released following adrenergic stimulation 
(norepinephrine 20 μmol/L or phenylephrine 20 μmol/L) was significantly reduced in SMC-
Cav1Δ/Δ mice compared with controls (Figure 3E). No significant effect on ATP release was 
observed in any of the genotypes tested in response to agonists for other potent 
vasoconstriction pathways (e.g., ET-1 or 5-HT) (Figure 3E). Intracellular ATP concentration 
was also unchanged in any of the genotypes tested (Supplemental Figure IV).
In line with our ATP findings, we reasoned that blunted adrenergic-mediated ATP release in 
SMC-Cav1Δ/Δ mice would concomitantly impair vascular responses to phenylephrine. To 
directly measure vasoconstriction responses in ex vivo resistance arteries, we assessed 
vascular responses to increasing concentrations of phenylephrine using pressure myography. 
SMC-Cav1Δ/Δ mice exhibited significant reductions in phenylephrine-stimulated 
vasoconstriction (red line) compared with control animals (black line) (Figure 4A). Unlike 
global caveolin-1 knockout mice, which exhibit reduced expression of endothelial cell 
caveolin-116,53, no significant differences were observed in endothelium-dependent 
vasodilation (acetylcholine responses) in SMC-Cav1Δ/Δ mice (Figure 4B). Thus, VSMC-
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specific deletion of caveolin-1 impairs adrenergic vasoconstriction without altering 
endothelial-mediated responses.
Previously we have shown that VSMC-specific deletion of Panx1 channels results in 
significantly reduced BP due to blunted adrenergic-stimulated ATP release and 
vasoconstriction. Thus, we used telemetry to test whether SMC-Cav1Δ/Δ mice exhibited a 
similar BP phenotype. BP was assessed in individual animals before (baseline) and after 
induction of caveolin-1 deletion. A significant reduction in 24-hour mean arterial pressure 
(total MAP= −3.8 mmHg) was observed only after tamoxifen injection in SMC-Cav1Δ/Δ 
mice (Figure 5A–B). Moreover, a significant and greater BP reduction (ΔMAP= −6.8 
mmHg) was observed during the active period, when sympathetic drive to resistance arteries 
is higher (Figure 5C) compared to the inactive period (Figure 5D). No significant difference 
in baseline MAP was observed in any other tested genotype before induction with 
tamoxifen, vehicle control, or saline control (Figure 5C; Supplemental Figure V). There was 
also no change in plasma renin concentration after caveolin-1 deletion, which was tested as a 
metric of altered basal renal-vasculature function (Supplemental Figure V).
To ensure that BP reductions in SMC-Cav1Δ/Δ mice were not influenced by changes in 
cardiac function, we performed functional MRI analysis on SMC-Cav1Δ/Δ and control 
animals (Figure 6). No significant changes in cardiac function were observed in any of the 
tested genotypes (Table 1). This includes cardiovascular changes due to heart rate, stroke 
volume, cardiac output, left ventricular mass, or left ventricular wall thickness–all of which 
can directly influence MAP. Lastly, mice lacking the Cre allele, but maintaining the loxP 
genotype and injected with tamoxifen, showed no changes in expression of caveolin-1 in 
arteries, phenylephrine dose-responses, or MRIs (Supplemental Figure VI; Supplemental 
Table I).
To functionally assess whether BP reductions involving VSMC caveolin-1 are mediated 
through a Panx1-dependent pathway, we acutely treated animals with the Panx1 intracellular 
loop mimetic peptide-inhibitor PxIL2P (20 mg/kg) or scrambled control peptide (20 mg/kg). 
We have previously shown that PxIL2P significantly blunts phenylephrine-stimulated Panx1-
channel currents, ATP release, vasoconstriction, and MAP22. Following acute injection of 
PxIL2P, significant BP reduction was restricted to vehicle treated SMC-Cav1fl/fl (vehicle 
treated: ΔMAP= −8.83 mmHg) and C57BL/6 (vehicle treated: ΔMAP= −12.26 mmHg; 
tamoxifen; ΔMAP= −9.81 mmHg) control animals–both of which contain VSMC 
caveolin-1. Conversely, no significant changes in MAP were observed in SMC-Cav1Δ/Δ 
animals, which are deficient in VSMC caveolin-1 (tamoxifen: ΔMAP= 0.73 mmHg; Figure 
7). Administration of a scrambled PxIL2P peptide of the same amino acid composition did 
not influence BP in any genotype tested. The resistance of VSMC-specific caveolin-1 
deficient mice to BP lowering by PxIL2P supports the idea that VSMC caveiolin-1 regulates 
BP homeostasis through changes in Panx1 localization and channel function.
DISCUSSION
Sympathetic-mediated vasoconstriction plays a central role in controlling BP homeostasis. 
This process occurs in part due to the release of norepinephrine from sympathetic nerves, 
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subsequent activation of VSMC α-ARs, and coordinated constriction between VSMCs, thus 
producing a unified vasoconstriction response. Recent work from our group revealed that 
VSMC Panx1 channels21 are a primary mediator of α-AR vasoconstriction, and using 
VSMC-specific Panx1 knockout mice and genetic rescue experiments we demonstrated that 
ATP release from tehse channels was necessary for proper adrenergic vasoconstriction21,54. 
In this way, ATP acts as an autocrine/paracrine signaling molecule that initiates 
vasoconstriction responses in resistance arteries. However, less is known about the 
intracellular signaling molecules responsible for supporting Panx1 channel function 
following adrenergic stimulation. Here we have identified a novel interaction between Panx1 
and the caveolae structural protein caveolin-1. Caveolin-1 and Panx1 localize to areas of the 
plasma membrane innervated by sympathetic nerves and associate with each other following 
stimulation of α-ARs with phenylephrine. Using a novel, inducible, VSMC-specific 
caveolin-1 knockout mouse, we also demonstrate that caveolin-1 functionally regulates 
adrenergic-mediated ATP release, vasoconstriction, MAP, and Panx1 dependent BP 
responses.
Plasma membrane caveolae influence vascular homeostasis and assist in the localization of 
key VSMC vasoconstriction signaling molecules such as α-AR and Gq coupled effector 
molecules in small arteries19,49,55. From electron microscopy observations (Supplemental 
Figure I), we often observe caveolae localized near sympathetic nerves, and thus predicted 
that this unique vascular feature may beget vascular function. Our live cell, fluorescent 
tracking experiments, allowed us to examine caveolin-1 and Panx1 interactions in response 
to stimulation with phenylephrine. Activation of α-AR resulted in a rapid co-association of 
the two proteins at the plasma membrane (Figure 1A–B). These temporal effects are 
consistent with previous constriction recordings following adrenergic stimulation in 
resistance arteries56,8. Moreover, we treated VSMCs with a high concentration of ATP (500 
μmol/L), a manipulation that promotes active internalization of membrane associated 
Panx150, to determine if caveolin-1 association correlates with Panx1 endocytosis. Here we 
observed a significant decrease in co-localization between Panx1 and caveolin-1 following 
ATP stimulation (Figure 1A–C), indicating that Panx1 endocytosis occurs independently of a 
caveolin-1 association.
Recent studies by Boyce et al.50 and Gehi et al.43 report similar co-distributions of Panx1 
with caveolin-1 in cell lines. In contrast to the phenylephrine-induced Panx1/caveolin-1 
clustering observed herein, a similar decrease in overlap with caveolin-1 was observed 
following ATP application in N2a cells.50 It is important to note in this context that 
caveolin-1-enriched caveolae are only one specialized variety of cholesterol-enriched 
membrane microdomain or lipid raft5. In fact, ATP-mediated Panx1 internalization is 
cholesterol-dependent50,51 but dynamin- and clathrin-independent43,50, suggestive of a non-
canonical endocytosis mechanism. Our novel results then suggest that inclusion of Panx1 in 
VSMC caveolae may alter channel activity (such as increased open probability57–59) rather 
than trafficking, although this remains to be explicitly tested. In light of this work, and 
because of the strong association between caveonlin-1 and Panx1 following adrenergic 
stimulation, we tested whether an endogenous interaction occurs in VSMCs. The same 
culture model also showed a specific protein interaction using immunoprecipitation of 
membrane fractions after phenylephrine stimulation (Figure 1D–F), which was absent in 
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non-caveolar Panx1-containing fractions. In these experiments, we observed multiple 
glycosylation species of Panx160,61 (between 37–55kDa) after immunoprecipitation, perhaps 
indicative of the recruitment of more Panx1 channels from intracellular stores following 
stimulation. Panx1 channels are oligomers of Panx1 subunits. It is unknown how many units 
within the channel must be glycosylated to allow for the appropriately trafficking of plasma 
membrane channels. It is plausible that Panx1 subunits are differentially regulated, which 
has been strongly suggested in other published work29. It also remains to unknown whether 
binding of Panx1 to caveolin-1 after phenylephrine stimulation requires a direct interaction, 
which has been observed for other membrane channels57–59, or if other membrane 
associated effector molecules are required, such as Src family kinases62,63.
Panx1 plays a vital role in α–AR vasoconstriction, but not in other constriction pathways22. 
We reasoned that caveolae might engender the formation of α–AR membrane microdomains 
near the VSMC membrane innervated by sympathetic nerves. Using intact mouse resistance 
arteries in conjunction with PLA, we observed an adrenergic-induced interaction of 
caveolin-1 and Panx1 preferentially localized around sympathetic nerves (Figure 2D–E). 
These observations suggest that caveolae may support the formation of a signaling 
microdomain important for Panx1 activation22. Moreover, resistance arteries are 
characterized by multiunit neural innervation to VSMCs, whereby small patches of VSMCs 
are contacted by sympathetic nerves to allow for finer individual control of 
vasoconstriction64. This innervation pattern differs from the unitary innervation observed in 
visceral organs and large arteries, which features a single VSMC neural input and relies on 
gap junction connectivity to synchronize constriction responses. In this study as in 
previously published findings 21, we detect a scarcity of gap junction connectivity between 
VSMCs in our models by Cx43 immunostaining herein (Supplemental Figure III) or 
electron microscopy21. These results suggest that resistance arteries may preferentially 
utilize autocrine/paracrine-mediated signals to couple VSMC constriction responses, and 
may further utilize purinergic signaling pathways mediated through Panx1 to facilitate this 
function.
The idea that spatially localized signals support vascular function has been extensively 
characterized in the endothelium, where regulation of tyrosine kinases and endothelial nitric 
oxide synthase is dependent on caveolin-15; however, less is known about these processes in 
VSMCs, which utilize sympathetic innervation to adjust vascular resistance for proper blood 
pressure control65. Perturbations to this adrenergic signaling axis may underlie clinical 
pathologies in patients suffering from treatment-resistant hypertension who present with 
enhanced sympathetic drive, norepinephrine spillover, and excessive vascular 
resistance66–68.
To explore the functional role of caveolin-1 in VSMCs we generated an inducible VSMC-
specific caveolin-1 knockout mouse (Figure 3A–B) to selectively removed caveolin-1 from 
the vascular media (Figure 3C). Importantly, caveolin-1 expression remained present in the 
vascular endothelium (CD31-positive cells) between control and knockout mice. No gross 
alterations in the medial wall thickness or cell number were observed in TDAs (data not 
shown) as was described for pulmonary arteries in the constitutive global knockout13. It is 
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likely that the utilization of an inducible Cre-recombinase system in adult mice curtailed any 
negative compensatory effects seen in constitutive systems.
Using ATP bioluminescence assays, we measured phenylephrine-stimulated ATP release 
from ex vivo arteries, a process that our laboratory has shown uniquely couples with Panx1 
activation22. In all cases, caveolin-1 deletion significantly reduced phenylephrine- and 
norepinephrine-stimulated ATP release, similar to observations in Panx1 VSMC-knockout 
mice22 (Figure 3E). From our immunofluorescence analyses, it seems likely that Panx1 is 
the primary conduit for ATP release from VSMCs, as VNUT and Cx43 were not detected in 
VSMCs of our vessels (Supplemental Figure III). These data suggest that caveolin-1 is 
involved upstream of Panx1 activation and influences the ATP release typically ascribed to 
Panx1 function. It remains to be demonstrated if a direct interaction between caveolin-1 is 
sufficient to induce Panx1 channel opening.
In the vasculature, a primary role for caveolin-1 is ascribed to negative regulation of 
endothelial nitric oxide synthase (eNOS) activity in the endothelium69,70. Global deletion of 
caveolin-1 increases eNOS activity, resulting in higher concentrations of cGMP, increased 
NO release, and alterations in myogenic tone and dilation responses to acetylcholine16,53. 
However, the role of VSMC-derived caveolin-1 has not been specifically examined in 
resistance arteries. Using pressure myography, we found that VSMC caveolin-1 deletion 
significantly blunts phenylephrine-stimulated vasoconstriction responses, but does not 
change vasodilation responses to acetylcholine (Figure 4A–B), indicating that reduced 
vasoconstriction is not dependent on endothelial-derived mechanisms observed in global 
caveolin-1 knockout models13. ATP release from the vascular wall exhibits dual activities in 
resistance arteries dependeing on which cell type release ATP (vasoconstriction in smooth 
muscles and vasodilation in endothelial cells) The subtypes of purinergic receptors that are 
activated by ATP can also influence responses within the vascular wall with the largest 
contribution in smooth muscle being mediated by P2X1 ionotropic receptors71. Our 
laboratory has demonstrated the existence of purinergic component to adrenergic mediated 
vascular events whereby incubation of vessels with the ATP degrading enzyme apyrase or 
pharmacological blockers of purinergic receptors (P2X) prevents adrenergic 
vasoconstriction21. Thus, we conclude that caveolin-1 in our model functionally regulates 
the initial and upstream release of ATP utilized to activate downstream purinergic receptors 
after adrenergic stimulation.
VSMC-specific deletion of caveolin-1 results in reduced adrenergic ATP release and 
vasoconstriction, a similar vascular phenotypic observed when Panx1 is specifically deleted 
from VSMCs. We predicted that a similar dysregulation in BP would then occur after 
caveolin-1 deletion as observed in Panx1 knockout models: specifically, a reduction in MAP 
predominantly during the animal’s active period (night MAP), when sympathetic drive is 
high. Indeed, in vivo BP monitoring revealed a significant reduction in 24 hour MAP (Figure 
5A–B) with a greater reduction occurring at night (Figure 5C) in caveolin-1-deficient 
animals, but not during the day (inactive period) (Figure 5D). The effect size of BP lowering 
due to caveolin-1 deletion (~4 mmHg, 24 hour MAP; ~6 mmHg, Night MAP) was nearly 
identical to BP reductions in VSMC-Panx1 knockout animals53. To further confirm that 
alterations in MAP were due to vascular changes (reduced vascular resistance), we assessed 
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cardiac function using MRI. No measurable morphological differences were detected in our 
analysis and all animals were functionally similar (e.g., heart rate, stroke volume; Table 1). 
Therefore, alterations in vascular resistance due to VSMC caveolin-1 deletion are likely 
responsible for observed reductions in MAP.
To determine if caveolin-1 dependent BP responses utilize in part a Panx1-dependent 
pathway, we acutely treated animals with PxIL2P peptide to pharmacologically lower blood 
pressure. PxIL2P has previously been shown to significantly reduce adrenergic stimulated 
Panx1 channel opening and ATP release, and also potently lowers blood pressure in mice. In 
the current analysis, wild-type and control mice dramatically respond to PxIL2P treatment 
(i.e reduced blood pressure lowering), with no effects due to scrambled control peptide22. 
However, conditional deletion of VSMC caveolin-1 are completely protected to BP lowering 
by PxIL2P treatment. This strongly suggests that caveolin-1 is a key intermediary necessary 
for normal Panx1 function (Figure 7). These data further highlight the Panx1 intracellular 
loop as an important target for Panx1 activation. Previous work from our group has 
demonstrated that the region mapping to the PxIL2P peptide contains a regulatory motif, 
which upon genetic mutation negatively influences Panx1 channel function and adrenergic 
mediated vasoconstriction22. Future studies are needed to determine if caveolin-1 directly 
influences the Panx1 intracellular loop, or if associative factors bound to caveolin-1 are 
required for proper channel function.
In this analysis, we explore a novel adrenergic vasoconstriction pathway that has previously 
been shown to coordinate constriction responses through the release of ATP by Panx1. We 
describe the impact of caveolin-1 deletion in the peripheral vasculature and on systemic BP 
regulation using a novel smooth muscle-specific mouse model. We have limited changes due 
to compensatory deletion-effects by utilizing an inducible Cre-lox system in adult mice. 
Based on our analyses we found no additional phenotypes outside of the cardiovascular 
phenotypes reported in this study. Although, direct experimental evidence and future studies 
are required to determine if additional phenotypes exist. Here we show that the localization 
of Panx1 to plasma membrane caveolae and the scaffold protein caveolin-1 promotes a novel 
interaction important for regulating BP. It remains to be observed whether other scaffold 
proteins or cytoskeletal proteins contribute to the localization and formation of this unique 
membrane domain near sympathetic nerve terminals in VSMC. Panx1 has been shown to 
directly interact with the actin cytoskeleton72 and its modulator actin-related protein 373,74, 
and treatment with cytochalasin B destabilized Panx1 plasma membrane distribution in 
vitro72. It is also unknown which intracellular mediators are mechanistically required for 
activation of Panx1 by α-AR in VSMCs, which will be especially important to determine.
Overall, our data demonstrate that Panx1 and caveolin-1 functionally couple with each other 
in VSMCs. Using immunofluorescence co-localization and co-immunoprecipitation, we 
show that caveolin-1 and Panx1 interact at distinct areas of VSMC plasma membrane 
innervated by sympathetic nerves, suggesting the existence of an adrenergic micro-signaling 
domain. This interaction was induced by α-AR stimulation and is necessary for adrenergic-
mediated vasoconstriction and ATP release from resistance arteries. We found that VSMC 
caveolin-1 is necessary to control systemic BP responses through modulation of Panx1 
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function and may facilitate appropriate channel function through the Panx1 intracellular loop 
region.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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NON-STANDARD ABBREVIATIONS AND ACRONYMS
Panx1 Pannexin 1
VSMC Vascular smooth muscle cell
BP Blood pressure
MAP Mean arterial pressure
TDA Thoracodorsal artery
PE Phenylephrine
α–AR α–adrenergic receptor
VNUT Vesicular nucleotide transporter
Cx43 Connexin43
Cav1 Caveolin-1
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PERSPECTIVES
A strong medical need exists for an effective, safe, and innovative pharmacological 
therapy that promotes BP regulation and reduces the vasoconstriction that accompanies 
excessive sympathetic stimulation. Our observations demonstrating an adrenergic-
mediated interaction between VSMC caveolin-1 with Panx1, and the subsequent 
caveonlin-1 dependent control of vascular responsiveness and blood pressure 
homeostasis, are important for expanding our knowledge of a novel adrenergic signaling 
pathway that may underlie treatment-resistant hypertension. In the future, our goal is to 
elucidate signaling partners involved forming functional adrenergic signaling 
microdomains and determine their applicability as targets for therapeutic intervention.
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HIGHLIGHTS
• Presents a novel interaction between the ATP release channel Pannexin1 and 
the caveolae scaffolding protein caveolin-1, which is mediated by adrenergic 
stimulation.
• Demonstrates that conditional genetic deletion of caveolin-1 from smooth 
muscle cells recapitulates Pannexin1 vascular phenotypes.
• Demonstrates that smooth muscle cell caveolin-1 regulates adrenergic 
stimulated vascular constriction and mean arterial pressure.
DeLalio et al. Page 22
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2019 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 1. Pannexin 1 and caveolin-1 only associate after phenylephrine stimulation
(A) Confocal images and line scan analysis of cultured human VSMCs expressing Panx1-
RFP and caveolin-1 GFP following phenylephrine stimulation. Scale bar; 50 μm (low-
magnification) and 10 μm (high-magnification) (B) Co-localization analysis of continuous 
time lapse confocal imaging in human VSMCs throughout acute stimulation (total time= 3 
min) with vehicle control (black line; n=11), 500 μmol/L ATP control (red line; n=5), or 100 
μmol/L phenylephrine (green line; n=10). *p < 0.05 compared to vehicle control using two-
way ANOVA with Dunnett’s posthoc. (C) Heat map representation of percent fluorescence 
co-distribution using Mander’s coefficient analysis and normalized to baseline 
(green=positive association; red=negative association). (D) Membrane fractionation and 
western analysis of VSMCs showing endogenous distribution of Panx1 and caveolin-1 in 
membrane fractions. (E) Subcellular distribution of caveolin-1 enriched membrane domains 
in sodium carbonate-based detergent-free cellular fractionation using a discontinuous 
sucrose gradient (5%–40%), analyzed by immunoblot. Panx1 co-fractionates with caveolin-1 
in lipid light rafts at the plasma membrane. (F) Co-immunoprecipitation and quantification 
of Panx1 and caveolin-1 from subcellular plasma membrane domains was measured 
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following phenylephrine stimulation, n=5. Data analyzed by student’s t-test and presented as 
mean ± SEM. * p < 0.05.
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Figure 2. Pannexin1 and caveolin-1 localize to the plasma membrane near sympathetic nerves
En face immunofluorescence detection of Panx1 and caveolin-1 using proximity ligation 
assay (PLA) on intact TDA. Sympathetic nerves were labeled with tyrosine hydroxylase 
(green) and nuclei were labeled with DAPI (blue). (A) Control IgG (rabbit) staining. (B) 
PLA secondary probe control. (C) Lack of positive PLA between Panx1 and caveolin-1 in 
VSMCs at baseline conditions. (D–E) Panx1 and caveolin-1 cluster at areas of sympathetic 
innervation following acute (1 min) phenylephrine treatment (20 μmol/L). Positive PLA 
amplification is visualized as red punctate spots (white arrows). (E) Quantification of PLA 
signal between Panx1 and caveolin-1 before and after treatment with phenylephrine. N=3 
animals per treatment group. Scale bar; 50 μm.
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Figure 3. Inducible deletion of caveolin-1 from smooth muscle cells functionally mimics blunted 
adrenergic-mediated ATP release in Pannexin 1 deletion
(A) Inducible SMMHC-CreERT2+/Cav1fl/fl (SMC-Cav1fl/fl) mice were injected with 
tamoxifen (1 mg/kg) to delete caveolin-1 (SMC-Cav1Δ/Δ). (B) Agarose gel from genomic 
DNA showing Cre-mediated recombination at loxP site in tamoxifen treated mice. (C) 
Immunostaining of transverse sections of TDAs with anti-caveolin-1 (red), internal elastic 
lamina (gray), α-SMactin (Acta2), or CD-31 (Pecam1) (green). Nuclei are stained with 
DAPI (blue). *indicates vessel lumen. Scale bar; 20 μm. Arrows in high magnification 
indicate endothelial cells. (D) Quantification of caveolin-1 deletion from VSMCs 
normalized to α-SMactin positive area; n=6 mice. Students t-test was performed, 
significance indicated by asterisk ***p < 0.001. (E) ATP release from intact TDAs in 
response to adrenergic vasoconstrictors: phenylephrine (PE; 20 μmol/L) and norepinephrine 
(NE; 20 μmol/L), or non-adrenergic vasoconstrictors: serotonin (5-HT; 40 nmol/L) and 
endothelin-1 (ET-1; 40 nmol/L). n = 4 mice. Data displayed as groups and represented as 
mean ± SEM. Two-way ANOVA and Tukey’s posthoc test was performed for significance; 
*p < 0.05.
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Figure 4. Effects of vascular smooth muscle cell caveolin-1 deletion on vasoconstriction and 
vasodilation responses in resistance arteries
(A) Contractile responses to increasing concentrations of phenylephrine in TDAs from 
SMC-Cav1fl/fl control mice (black line; N=4 mice (7 arteries)) and SMC-Cav1Δ/Δ 
tamoxifen-treated mice (red line; N=6 mice (8 arteries). (B) Effects of VSMC caveolin-1 
deletion on endothelial-dependent vasodilation to increasing concentrations of acetylcholine. 
Concentration-effect curves were fitted to the data using four-parameter, non-linear 
regression curve. Data assessed by two-way ANOVA with Bonferroni post-hoc test for 
multiple comparisons. **p < 0.01 ***p < 0.001.
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Figure 5. VSMC Caveolin-1 deletion reduces blood pressure
(A) 24 hour mean arterial blood pressure (MAP) of mice across the indicated genotypes. (B) 
Differences in 24 hour MAP (ΔMAP) across the indicated groups of mice after treatment 
with tamoxifen or vehicle control. (C) MAP during the nocturnal active period (12 hr dark: 
6:00PM–5:59AM), and (D) MAP during the daytime inactive period (12 hr light: 6:00AM–
5:59PM). Baseline measurements were made for each individual animal before injections 
and compared to BP responses 2 weeks after tamoxifen or vehicle control injection. N=4 
mice for each treatment group. *p < 0.05, **p < 0.01, ***p<0.001 compared to baseline 
response using one-way ANOVA (B) or two-way ANOVA (A, C, D), with Tukey’s posthoc 
test.
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Figure 6. VSMC caveolin-1 deletion does not influence cardiac function
Representative transverse and sagittal MRI images of SMC-Cav1fl/fl control and SMC-
Cav1Δ/Δ hearts. Six short-axis slices were acquired from base to apex, with slice thickness 
equal to 1mm, in-plane spatial resolution of 0.2 × 0.2 mm2, and temporal resolution of 8–12 
ms. No differences in size, morphology, or function were detected as summarized in Table 1.
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Figure 7. Caveolin-1 deletion prevents the blood pressure-lowering effects of the Panx1 
inhibitory peptide (PxIL2P)
Differences in MAP (ΔMAP) measured at baseline and 2 hrs after treatment with the Panx1 
inhibitory peptide PxIL2P (20 mg/kg) or scramble control (20 mg/kg) in SMC-Cav1fl/fl, 
SMC-Cav1Δ/Δ, or C57BL/6 mice. Changes in MAP were calculated using each animal’s 
individual baseline pretreatment. n=4 mice for each treatment group; *p< 0.05 and **p< 
0.01 compared to individual baseline response using two-way ANOVA and Tukey’s test.
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